Image

Founded in 1997, MedSource is a full-service niche clinical research organisation (CRO), specialising in oncology programs and other complex clinical trials. We have participated in more than 700 clinical trials globally, with over 200 of them occurring in the area of oncology. MedSource’s efforts support biopharmaceutical clients who conduct complex trials in the most challenging disease states. The firm’s experience encompasses a range of therapeutic areas, product types, clinical trial phases and study designs.

Over the years, MedSource’s services have expanded to include clinical monitoring, clinical project management, regulatory affairs and submissions, quality assurance (QA) auditing, study startup services, feasibility and site selection, data management, biostatistics, safety reporting, as well as medical monitoring.

MedSource’s goal is for our clients to return to us when they need high-quality clinical trial support. It is our role to be a trusted advisor and to act with our clients’ best interests in mind. Our clients trust that we will get the job done, with minimal management required.

Each time MedSource undertakes a new client, our approach remains the same as it has been for the last 19 years, we approach every opportunity with a customised solution.
In regards to MedSource’s staff, they are passionate, genuine and critically focused on integrity and results. The team you meet at the start are the ones who work on your project. We are candid and transparent about all of our processes, and we provide line-item bids, so you see everything up front.

Going forward, MedSource are very excited about our prospects for the future and we are keen to increase the number of services we currently offer. With 6 locations throughout the US and Europe, we are prepared to handle our clients’ complex clinical trials.


Company: MedSource

Name: Eric Lund

Web: www.medsource.com

Address: 16902 El Camino Real, Suite 1A Houston, TX 77058 USA

Telephone: 1 (281) 286 200

Share this page:
Copyright Acquisition Intl. 2016